Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive ...
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 development Company to host webcast call Monday …